Skip to main content
Ghassan Abou Alfa on Muck Rack

Ghassan Abou Alfa

New York
As seen in: National Institutes of Health, Nature, Wiley Online Library, MDPI, JAMA Oncology, Medscape, The New England Journal of Medicine, The Lancet, Healio, NewsBreak and
@MSKCancerCenter Medical Oncologist, liver, cholangiocarcinoma, gallbladder, biliary cancer specialist. Global healthcare specialist. Patients’ advocate.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ghassan Abou

Contact Ghassan Abou, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

HIMALAYA Overall Survival Prominence and Other Routes to the Peak

|
By Ghassan Abou Alfa, Bruno Sangro, Sarah Cappuyns
| JAMA Oncology Verified
HIMALAYA Overall Survival Prominence and Other Routes to the Peak Critical Appraisal of Recommendations on Systemic Therapies for Advanced HCC Sarah Cappuyns, MD; Virginia Corbett, MD; Mark Yarchoan, MD; Richard S. Finn, MD; Josep M. Llovet, MD, PhD HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply Josep M. Llovet, MD, PhD; Sarah Cappuyns, MD, PhD; Richard S.
Open in Who Shared Issue with article?

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

|
By Ghassan Abou Alfa, George Lau, Masatoshi Kudo, Stephen Chan
| Future Medicine Verified
This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article here Financial & competing interests disclosure This study was sponsored by AstraZeneca. We thank the participants in this study and their families, all the investigators and study site personnel, and the members of the independent data monitoring committee.
Open in Who Shared Issue with article?

Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data - npj Precision Oncology

|
By Travis Zack, Atul J. Butte, Ghassan Abou Alfa, Kurt P. Losert
| Nature Verified
Abstract The incidence and biochemical consequences of rare tumor subtypes are often hard to study. Fibrolamellar liver cancer (FLC) is a rare malignancy affecting adolescents and young adults. To better characterize the incidence and biochemical consequences of this disease, we combined a comprehensive analysis of the electronic medical record and national payer data and found that FLC incidence is likely five to eight times higher than previous estimates.
Open in Who Shared Issue with article?
See all 45 licensed articles (94 Total)